Monte Rosa Therapeutics GLUE Cash Flow Statement (2020-2026)

NASDAQ GLUE
$13.98 -0.40 (-2.82%)
As of: Sep 4, 2026 · 2:20 PM EDT
Reported Financials

Monte Rosa Therapeutics Quarterly Cash Flow Statement

Periods 25 quarters
Latest Jun 2026

Monte Rosa Therapeutics reported cash from operations of -$44.11M and free cash flow of -$47.97M for the quarter ended Jun 2026, down 27.1% year over year. This cash flow statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-19.86M-23.37M-24.15M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.25M-31.98M-30.31M-23.86M30.73M46.88M-12.29M-27.08M-38.92M-44.55M-43.40M
Share-based CompensationStock Comp.
26.10M1.86M7.10M35.50M32.60M3.33M10.10M37.90M33.10M4.07M11.71M11.54M11.59M4.47M15.15M15.19M14.94M4.31M15.99M15.94M
Cash from OperationsCash from Ops.
-17.79M-14.17M-27.40M-20.50M-20.60M-23.96M-23.41M-25.32M-24.71M29.63M-38.16M-27.77M-20.99M128.92M-45.49M-34.72M100.43M-43.01M-37.37M-44.11M
Change in Working Capital
Change in Account PayablesChange Payables
-4.25M4.74M-2.18M-0.36M1.65M0.15M0.31M-1.00M0.69M5.77M-5.07M0.39M-2.38M13.31M-10.87M-1.10M8.88M-10.61M4.38M-1.49M
Change in Accured ExpensesChange Accured Exp.
5.88M-0.14M-3.56M1.36M1.16M2.07M-3.29M2.77M2.79M1.29M-3.89M2.04M2.33M3.70M-2.61M-2.47M4.19M8.73M-3.71M2.21M
Investing Activities
Capital ExpendituresCapex
1.75M3.06M1.69M2.55M1.40M7.27M9.18M6.51M1.66M1.69M1.38M2.02M0.40M0.18M1.59M1.70M0.65M0.77M2.74M3.85M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.01M0.12M-0.02M0.06M
Change in Acquisitions & DivestmentsChange Acquisitions
40.00M90.30M47.70M51.70M25.00M45.10M43.50M67.31M14.82M70.52M37.25M39.37M46.05M104.76M89.36M72.87M51.94M
Cash from Investing ActivitiesCash from Investing
-1.69M-3.05M-180.52M-14.25M29.49M-53.94M20.33M18.55M35.63M14.30M9.85M-61.16M37.75M-30.90M-100.23M25.32M38.14M-65.07M-261.00M-28.86M
Financing Activities
Other financing activitiesOther financing
31.01M0.15M0.10M0.08M0.11M0.02M0.90M1.10M22.98M0.25M49.75M0.01M0.35M5.36M4.52M2.60M
Cash from Financing ActivitiesCash from Financing
29.46M-0.14M0.15M0.10M-0.22M20.43M0.02M1.20M1.10M25.17M0.25M98.02M0.01M0.61M0.01M0.36M0.35M29.62M328.33M3.21M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
3.93M1.67M2.24M2.67M3.39M2.54M3.04M3.57M3.91M2.57M
Net Equity Issued and RepurchasedNet Equity Issued
13.51M6.55M24.25M
Additional items
Change in Cash
9.97M-17.35M-207.77M-34.65M8.67M-57.47M-3.06M-5.57M12.02M69.10M-28.07M9.10M16.77M98.63M-145.71M-9.03M138.91M-78.46M29.97M-69.76M
Free Cash FlowFCF
-19.55M-17.23M-29.09M-23.05M-22.00M-31.23M-32.59M-31.84M-26.36M27.95M-39.55M-29.79M-21.39M128.74M-47.08M-36.41M99.78M-43.78M-40.10M-47.97M
Net Cash FlowNCF
9.97M-17.35M-207.77M-34.65M8.67M-57.47M-3.06M-5.57M12.02M69.10M-28.07M9.10M16.77M98.63M-145.71M-9.03M138.91M-78.46M29.97M-69.76M